Q-omics provides the consensus-scored BRD7P4 profile across patient tissues and cancer cell-line models. BRD7P4 expression is associated with patient survival in 19 of 34 cancer types, with the highest sampling consensus in LGG. Among the 18 cancer types available for tumor–normal comparison, BRD7P4 is differentially expressed in 3, with the highest sampling consensus in COAD. Additionally, BRD7P4 RNA expression shows 13,811 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight LGG, COAD, and GBM as cancer lineages where BRD7P4 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for BRD7P4 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes BRD7P4 survival associations across molecular data types. BRD7P4 RNA expression shows survival associations in the most cancer types (19). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible BRD7P4 RNA expression–survival associations across cancer types. High BRD7P4 expression shows unfavorable associations in LGG, LUAD, LIHC and BLCA, but favorable associations in GBM and KIRC. The LGG Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .001). Together, the overview and detailed table identify LGG as the clearest survival context for BRD7P4 RNA expression.
This table summarizes BRD7P4 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 3. The strongest signals are observed in COAD for RNA.
This table ranks reproducible tumor–normal expression differences for BRD7P4. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. BRD7P4 shows lower tumor expression in PAAD and BRCA and higher tumor expression in COAD. The COAD box plot shows higher BRD7P4 RNA expression in tumor versus normal tissue (log2 FC = +0.096, t-test p = .009).
This table shows molecular features associated with BRD7P4 in patient tissues and cancer cell lines. In patient samples, BRD7P4 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set.
